



MEDTECS INTERNATIONAL CORPORATION LIMITED

(Incorporated in Bermuda)

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE CATALIST RULES AND UPDATES ON THE GROUP'S JOINT VENTURE WITH ACO INTERNATIONAL LIMITED

The Board of Directors (the "**Board**") of Medtecs International Corporation Limited (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to announce the following in respect of the second half of the full financial year ended 31 December 2021 ("**FY2021**") pursuant to Rule 706A of the Listing Manual Section B: Catalist Rules of the Singapore Exchange Securities Trading Limited ("**SGX-ST**").

Incorporation of subsidiaries

The Company's wholly-owned subsidiary, Hangzhou Jincheng Medical Supplies Manufacture Co., Ltd., had incorporated Hangzhou Jincheng Medical Technology Co., Ltd. ("**Jincheng Technology**") as a wholly-owned subsidiary on 14 October 2021. The current directors of Jincheng Technology are Mr. William Yang, Mr. Gary Yang Ker-Yi and Ms. Wan-Chien Yang. As a newly incorporated company, it is currently not generating revenue or engaging in any business activity.

It was disclosed in the Company's announcement dated 13 August 2021, that the Company's joint venture company, Resilient Medical Pte Ltd. ("**Resilient Medical**"), had incorporated RMKH Glove Pte. Ltd. ("**RMKH Glove**") on 16 March 2021. On 1 December 2021, RMKH Glove incorporated RMKH Glove (Cambodia) Co., Ltd. in Cambodia ("**RMKH Cambodia**") as its wholly-owned subsidiary, with an issued and paid-up share capital of US\$2,500,000 comprising 250 ordinary shares. The current directors of RMKH Cambodia are Mr. Clement Yang, Mr. William Yang, Ms. Wan-Chien Yang and Mr. Vireak Kao. As a newly incorporated company, it is currently not generating revenue or engaging in any business activity.

Please refer to the table below for further information on Jincheng Technology and RMKH Cambodia:

Country	Company Name	Shareholding Percentage Held by the Company	Issued and paid-up Capital / Registered Capital	No. of Shares	Date of Incorporation	Principal Activities
China	Hangzhou Jincheng Medical Technology Co., Ltd.	100%	RMB 500,000	NA	14 October 2021	Sale of hygiene products, medical equipment and disposable medical supplies
Cambodia	RMKH Glove (Cambodia) Co., Ltd.	70.6%	US\$2,500,000	250	1 December 2021	Manufacturing and sale of gloves

Subscription of shares in joint venture company and subsidiary

Resilient Medical

Further to the Company's announcement dated 22 November 2021 (the "**Announcement**") on updates to the Group's joint venture with ACO International Limited (the "**Joint Venture**"), the Board wishes to update that on 23 December 2021, the Company's wholly owned subsidiary, Medtecs (Asia Pacific) Pte. Ltd. ("**MAP**"), and ACO International Limited ("**ACO**") had entered into the share subscription agreement ("**SSA**") and shareholders' agreement principally on the terms disclosed in the Announcement.

As at 31 December 2021, MAP and ACO have subscribed for, and Resilient Medical has allotted and issued: (a) 5,999,000 ordinary shares to MAP for an aggregate consideration of US\$5,999,000 in cash; and (b) 2,500,000 ordinary shares to ACO for an aggregate consideration of US\$2,500,000 in cash.

Following the aforesaid share subscription, the issued and paid-up share capital of Resilient Medical as at 31 December 2021 is US\$8,500,000 comprising 8,500,000 ordinary shares, and MAP and ACO hold 6,000,000 and 2,500,000 ordinary shares in Resilient Medical, representing 70.6% and 29.4% of its issued share capital, respectively. Subsequent to 31 December 2021, ACO will subscribe for a further 500,000 ordinary shares in Resilient Medical for an aggregate consideration of US\$500,000, representing the balance of its initial capital injection under the SSA. As disclosed in the Announcement, ACO also has the right, subject to the fulfilment of certain specified conditions, to subscribe for an additional 500,000 or 1,000,000 ordinary shares in Resilient Medical at an issue price of US\$1.00 per ordinary share, which right must be exercised within 90 days of the completion of the initial capital injection. In the event ACO does not exercise such additional subscription right or does not subscribe for the full entitlement of 1,000,000 ordinary shares, MAP will have the right to subscribe for the balance entitlement of shares, which would result in MAP's shareholding in Resilient Medical being increased to up to 7,000,000 ordinary shares.

RMKH Glove

Further to the Announcement, the Board wishes to update that Resilient Medical had on 7 September 2021 increased its investment in RMKH Glove from US\$1,000 to US\$2,000,000 by subscribing for an additional 1,999,000 ordinary shares in cash, at US\$1.00 per share. As of the date of this announcement, Resilient Medical holds 2,000,000 ordinary shares in RMKH Glove, representing 100% of its issued and paid-up share capital.

The subscription of additional shares in Resilient Medical and RMKH Glove is intended to finance the working capital and capital expenditure requirements of the Joint Venture.

The incorporation of the above subsidiaries and the additional investment into Resilient Medical and RMKH Glove was funded by internal resources and is not expected to have any material impact on the net tangible assets and earnings per share of the Company for the current financial year ending 31 December 2022.

None of the Directors or controlling shareholders of the Company have any interest, direct or indirect, in the above other than through their shareholdings in the Company.

Submitted by Mr Clement Yang, Executive Chairman, on 1 March 2022 to the SGX-ST.

Media / Investor Relations Contact:

Citigate Dewe Rogerson Singapore Pte Ltd

Ms Samantha Lee / Mr Justin Teh

Tel: +65 6534 5122

Email: investor.relations@medtecs.com

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd, ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**Exchange**"). The Sponsor has not independently verified the contents of this announcement including the accuracy or completeness of any of the figures used, statements, opinions or other information made or disclosed.*

This announcement has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact persons for the Sponsor are Ms Evelyn Wee (Tel no.: +65 6232 0724) and Mr Howard Cheam Heng Haw (Tel no.: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View, Marina One West Tower, #06-07 Singapore 018937.